sasanlimab
sasanlimab is a pharmaceutical drug with 20 clinical trials. Currently 7 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
16
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 12 finished
100.0%
12 ended early
7
trials recruiting
20
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Clinical Trials (20)
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
All 20 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 20